The clinical disease course of ulcerative colitis (UC) varies substantially between individuals and can currently not be reliably predicted.
patients diagnosed at .50 years of age as compared with ,30 years of age; also extensive colitis, elevated erythrocyte sedimentation rate, anemia, and fever at diagnosis were associated with an increased risk of colectomy. 2 Other factors associated to severe disease course have been extensive disease 4, 5 and high serum interleukin 17A levels 6 at diagnosis. Further variables, such as serologic, fecal, and genetic markers, have been evaluated without sufficient predictive ability. 7 Recently, the role of the microbiota in the pathogenesis of various intestinal diseases has been assessed and patients with UC demonstrate dysbiosis with reduced microbial diversity. [8] [9] [10] In close interplay with the microbiota is the anti-inflammatory response of the host, orchestrated by innate immune cells and cells lining the gut epithelium. These cells express different antimicrobial peptides to keep bacteria secluded from the epithelial lining. Among the antimicrobial peptides, bactericidal/permeability-increasing protein (BPI) is one of our most potent natural antibiotics and is produced not only by epithelial cells 11 but also by neutrophils during inflammation. 12 BPI is a small cationic peptide with high affinity for lipopolysaccharide (LPS) from the cell wall of gram-negative bacteria. 13 Apart from its bactericidal and neutralizing abilities, it also minimizes the inflammatory response of the host by directing BPI-coated gram-negative bacteria and free LPS to neutrophils for removal via phagocytosis, thus circumventing the pro-inflammatory CD14/TLR4 activation in macrophages. 14, 15 Increased mucosal levels of BPI have been reported previously during inflammation in UC. 16, 17 It has also been shown that patients with UC have increased serum levels of antineutrophil cytoplasmic antibodies against BPI, which may hamper the antimicrobial effects. 18, 19 The unpredictable disease course of UC at disease onset prevents individualized treatment, which is currently not a valid option in clinical practice. In this study, we hypothesized that the fecal microbiota and the host's innate immune response at the time of diagnosis are associated with the disease course. Therefore, we determined fecal microbiota composition and mucosal antibacterial response pattern in patients with newly diagnosed UC. Data obtained were correlated to the disease outcome during 3 years follow-up in patients defined as having a mild or a moderate/severe disease course.
MATERIALS AND METHODS

Study Subjects and Sample Specimens
Forty-eight patients with newly diagnosed UC among patients referred to the inpatient and outpatient clinics and the endoscopy units at Sahlgrenska University Hospital (Gothenburg, Sweden) and Södra Älvsborgs Hospital (Borås, Sweden) were included into the study. The inclusion criteria of the study were newly diagnosed patients with UC (18-75 yrs), based on endoscopic and histological findings, and without medical treatment for IBD. Exclusion criteria were other severe diseases, such as heart, lung, or neurological disease, active malignancies, and antibiotic use during the month before inclusion. The extent of the disease and the endoscopic disease activity were established with colonoscopy or sigmoidoscopy. The disease activity was determined by Mayo score, which included the score from the endoscopic examination. 20 The extent of disease was classified into proctitis, left-sided colitis, or extensive colitis (beyond the left colonic flexure) according to the Montreal classification. 21 Serum and biopsy samples were obtained from all patients (n ¼ 48) and stool samples from 18 patients. Serum samples were stored at 2808C. Biopsies were collected in RNAlater (Ambion, Austin, TX) and kept at 2808C until RNA extraction or in Histocon (Histolab Products AB, Göteborg, Sweden) and subsequently placed in plastic forms (Cryomold; Miles Inc., Elkhart, IN) filled with O.C.T. Compound (Miles Inc.), snap frozen in isopentane in liquid N 2 for approximately 60 seconds, and then stored at 2808C until processed further. Stool samples were stored at 2208C until analysis.
Additionally, rectal biopsies were obtained from 7 individuals undergoing colonoscopy for other reasons than inflammation (polyps, weight loss). In addition, 4 healthy subjects were recruited for in vitro analysis of peripheral blood mononuclear cells (PBMCs). None of the noninflamed subjects in the study were taking any medications known to affect the gastrointestinal tract, gut microbes, or the immune system.
Subgrouping of Patients with Newly Diagnosed UC
From the time point of diagnosis of UC, patients were followed clinically for 3 consecutive years, during which the disease severity and the colonic disease extent were assessed yearly. The patients were defined to have a mild disease course or a moderate/severe disease course based on the numbers and severity of flares during the years (excluding the flare at diagnosis). A flare was defined as an episode of at least 2 weeks where symptoms exceeded baseline severity of symptoms and the majority of flares (.95%) persisted for 2 to 8 weeks. The severity of the flares were graded as mild, moderate, or severe based on the physician's global assessment with the help of symptoms (stool frequency, rectal bleeding) and, if existing, endoscopy. All patients with #2 flares and patients with 3 to 4 flares of no more than mild severity grade during the years were defined to have a mild disease course. All patients with $5 flares and patients with 3 to 4 flares where any of the flares had a severity grade of moderate or severe during the years were defined to have a moderate/severe disease course.
Microbiota Analysis
Microbiota analysis of fecal samples was performed using the GA-map Dysbiosis test (Genetic Analysis AS, Oslo, Norway). The GA test is based on molecular biology techniques, comprising human fecal sample homogenization and mechanical bacterial cell disruption; automated total bacterial genomic DNA extraction using magnetic beads; 16S rRNA polymerase chain reaction (PCR) DNA amplification covering V3-V9; probe labelling by single nucleotide extension; hybridization to complementary probes coupled to magnetic beads; and signal detection using BioCode 1000A 128-Plex Analyzer (Applied BioCode, Santa Fe Springs, CA). 10 The GA test consists of 54 DNA probes targeting $300 bacteria on different taxonomic levels and generates a bacterial profile based on 15 different bacteria (defined by Genetic Analysis AS): Ruminococcus albus/bromii, Ruminococcus gnavus, Faecalibacterium prausnitzii, Lactobacillus, Streptococcus sanguinis and Streptococcus salivarius thermophilus, Dialister invisus, Akkermansia muciniphila, Bacteroides fragilis, Alistipes, Shigella/ Echerichia, Bifidobacterium, Bacteroides/Prevotella, Firmicutes (Bacilli), Firmicutes (Clostridia), and Proteobacteria. The model algorithmically assesses fecal bacterial abundance and profile, and potential clinically relevant deviation in the microbiome from normobiosis and the output is a bacterial profile and a Dysbiosis index score. Dysbiosis indexes .2 (maximum 5) indicates a microbiota that differs from the healthy reference group.
Messenger RNA Extraction from Mucosal Biopsies
Total messenger RNA (mRNA) from mucosal biopsies was extracted using Nucleospin DNA, RNA, and protein purification Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer's protocol. RNA concentration and purity were measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, Delaware) with 260/280 and 260/230 ratios of ;2 and 2.1 to 2.2, respectively. Samples from 4 out of 48 patients had insufficient RNA quantity for the study.
RT 2 Profiler PCR Array
Complementary DNA was prepared using the RT 2 First Strand Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. The RT 2 Profiler PCR array for "Antibacterial response" (PHAS-148Z; Qiagen) was analyzed in a CFX384 Touch Real-Time (RT) PCR Detection System (BioRad, Hercules, CA) by the use of RT 2 qPCR SYBR Green MasterMix (Qiagen). Data were analyzed in the CFX Manager software (BioRad) and the RT 2 Profiler PCR Array Data Analysis version 3.5 (Qiagen). All samples except two passed the quality checks for PCR Array reproducibility, RT efficiency, and genomic DNA contamination. GAPDH and HPRT1 were chosen as housekeeping genes. A complete list of the genes in the array is shown in Table 1 , Supplemental Digital Content 1, http://links.lww.com/IBD/B501.
Quantitative RT-PCR Analysis
Complementary DNA was prepared using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer's protocol. Complementary DNA was then used for RT-PCR using Taqman Universal PCR MasterMix (Applied Biosystems, Foster City, CA) and Taqman Gene Expression assays (Applied Biosystems) according to the manufacturer's protocol. Expression of BPI (Hs01552756_m1), conserved helix-loop-helix ubiquitous kinase (CHUK, Hs00989502_m1), and chemokine (C-X-C motif) ligand 2 (CXCL2, Hs00601975_m1) was determined. Amplification was carried out using a 7500 RT-PCR system (Applied Biosystems), and all samples were run in triplicate. The results were normalized to the expression level of GAPDH (Hs03929097_g1) and HPRT (Hs02800695_m1) and expressed as 2-(Target-Housekeeping) .
PBMC Cultivation Assay and Flow Cytometry Analysis
PBMCs were isolated from heparinized venous blood from healthy volunteers by density gradient centrifugation using FicollPaque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Cells were cultured in Iscove's medium supplemented with 100 mg/mL gentamicin, 3 mg/mL L-glutamine (all from Sigma-Aldrich, St Louis, MO), and 10% fetal bovine serum (Gibco by Thermo Fisher Scientific, Waltham, MA). Cell cultures from each subject were stimulated with a final concentration of 1 ng/mL LPS (Sigma-Aldrich) or 10 mg/mL peptidoglycan (tlrl-pgnb2; Invivogen, San Diego, CA) with and without addition of 0.02, 0.2, or 2 mg/mL BPI (SRP6307; Sigma-Aldrich) in flat-bottomed 96-well plates (Nunc, Roskilde, Denmark). Before addition to the cells, LPS or peptidoglycan were preincubated with or without BPI at 378C for 15 minutes. The preincubation step was performed at 10· concentration in a total volume of 20 mL 0.1 M citric acid buffer (pH 5.5). Subsequently, 180 mL supplemented media was added to generate a 1· solution, the mixture was added to the cells, and the plates were incubated for 18 hours at 378C. Cell culture supernatants were collected and stored at 2808C at the end of the cell culture. Cultured cells were stained for flow cytometry analysis using the following antibodies: anti-HLADR-Alexa700, anti-CD14-PeCy7, anti-CD80-APC, lineage markers (anti-CD3-PE-CF594, anti-CD19-PE-CF594, anti-CD56-PE-CF594) (all from BD Biosciences, San Jose, CA). 7-Aminoactinomycin D (BD Biosciences) was used according to the manufacturer's protocol to exclude nonviable cells. Flow cytometry analysis was performed using an LSR II flow cytometer (BD Pharmingen, San Jose, CA). The data were analyzed using Flow Jo software (Treestar Inc., Ashland, OR).
Analysis of CXCL2 Protein and Anti-BPI antibodies
Serum samples were analyzed by enzyme-linked immunosorbent assay for levels of CXCL2 protein (Human MIP2 EnzymeLinked Immunosorbent Assay Kit; Abcam, Cambridge, MA) and anti-BPI-IgG antibodies (Demeditec Diagnostics GmbH, Kiel, Germany) according to the manufacturers' instructions. In vitro PBMC cultivation supernatants were analyzed for levels of CXCL2 protein (Abcam).
Immunohistochemistry
Frozen sections were prepared (7 mm) on microslides with a cryostat (Leitz, Wetzlar, Germany), fixed in 100% ice-cold acetone, blocked in phosphate-buffered saline with 1% bovine serum albumin and 5% goat serum, and stained with polyclonal rabbit-anti-BPI-IgG (PA5-26069, diluted 1:200; Thermo Fisher Scientific) followed by goat-anti-rabbit-AlexaFluor488 (Molecular Probes A11008, diluted 1:50; Invitrogen). Mounting was performed with 4 0 , 6-Diamidino-2-Phenylindole Dihydrochloride (DAPI)-UltraCruz mounting medium (sc-24941; Santa Cruz Biotech, Santa Cruz, CA). Fluorescence was visualized on a Zeiss AX10 Imager Z2 microscope at ·20 magnification.
Data Analyses
To examine the relationship between patients with mild and moderate/severe disease course (Y variable) and various mRNA levels or bacteria (X variables), multivariate factor analysis (SIMCA-P+ software; Umetrics, Umeå, Sweden) was used. Orthogonal partial least squares discriminant analyses (OPLS-DA) were implemented to correlate a selected Y variable and multiple X variables with each other in linear multivariate models. The quality of OPLS-DA was based on the parameters R2, i.e., the goodness of fit of the model (values of $0.5 define good discrimination, best possible fit, R2 ¼ 1), and Q2, i.e., the goodness of prediction of the model (values of $0.5 define high predictive ability). In the OPLS-DA loading scatter plots, each X variable is shown in relation to Y. The X variables positioned furthest to the left or right are more closely related to the respective Y variable and thus contribute most to the model.
The Mann-Whitney U test and the chi-square test were used to evaluate differences between 2 groups, Spearman's rank correlation coefficient was used to test the association between 2 variables, and Friedman's test was used to test the difference between several related samples. Linear regression analyses were used to model relationships between a dependent variable and explanatory variables. All values were logarithmized before use in regression analyses. Validation of the regression analyses was performed for (1) normally distributed residuals, (2) homoscedasticity of residuals, (3) linearity of regression function, (4) independence of error terms (Durbin-Watson test), and (5) outlier observations. Defined by Cook's distance and leverage values, data from one patient were considered as being an outlier and were excluded from further analyses.
All statistical analyses were performed using IBM SPSS Statistics 23; P values ,0.05 were considered statistically significant. Data are shown as median (range) or median (interquartile range), as defined in the text. Power analysis to estimate size of patient cohorts was not included in the experimental design because it was an exploratory study.
Ethical Considerations
The study was performed after receiving written informed consent from all subjects, and the protocol was approved by the Regional Ethical Review Board at the University of Gothenburg. Evaluators of the disease course were blinded to laboratory data, and evaluators of the laboratory analyses were blinded to the disease course of the individual patients.
RESULTS
Clinical and Demographic Characteristics of Patients with Newly Diagnosed UC
Among the 48 patients with newly diagnosed UC, 19 were defined to have a mild disease course and 29 were defined to have a moderate/severe disease course during the 3 years follow-up, according to our definition. Among the patients with a mild disease course, 10 patients had #2 flares, 4 patients had 3 flares, and 3 patients had 4 flares during the 3 years and all flares were graded as mild. Among the patients with a moderate/severe disease course, 5 patients had 3 flares, 4 patients had 4 flares, and 20 patients had $5 flares during the 3 years and 1 patient was colectomized during year 3. The patient groups showed no differences in gender distribution, age, smoking habits, disease extension, total Mayo score, endoscopic Mayo score, body mass index, C-reactive protein, or calprotectin at the time of UC diagnosis (Table 1) .
There was a strong agreement between the definitions of a mild or a moderate/severe disease course concerning medical care for gastrointestinal symptoms and medical therapy during the 3 years follow-up. Patients with a moderate/severe course were more health care seeking, more often hospitalized, and more frequently used 5-aminosalicylic acid and thiopurines during years 1, 2, and 3 as compared with the mild disease group (Table 2) . Corticosteroid use was more frequent for patients with a moderate/severe disease course during year 1, whereas during years 2 and 3, corticosteroid use was similar between the groups (Table 2) .
Fecal Microbiota Composition in Patients with Newly Diagnosed UC Is Associated with Disease Course
To investigate if the fecal microbiota was associated with disease course, the microbial composition of stool samples Multivariate analysis revealed that fecal microbiota composition at the time of UC diagnosis differed between patients who had a mild versus a moderate/severe disease course, including the total set of bacteria (Fig. 1A) . The model showed a good R2 value (0.55), defining a good separation between the groups, but a low Q2 value (20.80), showing low predictive ability. The OPLS-DA loading scatter plot showed that no single bacteria at the diagnosis of disease defined either patients with a mild disease course or patients with a moderate/severe disease course because all X variables (bacteria) were distributed relatively close to the mid-vertical line (Fig. 1B) . Nevertheless, a bacterial composition with higher abundance of Proteobacteria and Streptococcus was seen in patients with a moderate/severe disease course, whereas a composition including higher abundance of Ruminococcus and Akkermansia was demonstrated in patients with a mild disease course (Fig. 1B) . Together, these data suggest that there are differences in the fecal microbial composition, but without strong prognostic value, between patients with newly diagnosed UC who will have a mild or a moderate/severe disease course over a 3-year follow-up period. 
Mucosal Antibacterial Response Profile in Patients with Newly Diagnosed UC Is Associated with Disease Course
The composition of the gut microbial milieu develops in symbiosis with the host's innate immune response. Thus, an exploratory mRNA array was performed to study the mucosal antibacterial response profile in biopsies obtained from the patients at diagnosis. Samples from the patients with gut microbiota profiling were intended for inclusion in these analyses, but 2 samples did not pass quality control for the array (mild n ¼ 1, moderate/severe n ¼ 1) and 3 samples had insufficient RNA quantity (mild n ¼ 1, moderate/ severe n ¼ 2), which resulted in 13 patients for these analyses. The overall mucosal antibacterial response profiles at the time of UC diagnosis showed excellent discrimination and high predictive ability when comparing patients with a mild and a moderate/severe disease course, respectively ( Fig. 2A, R2 ¼ 0.98, Q2 ¼ 0.56). The most important nominators for the discrimination between the groups were higher expression of CXCL2 for patients with a moderate/ severe disease course, whereas patients with a mild disease course had higher expression of BPI and CHUK (Fig. 2B) . Among the 84 genes, 25 had a variable influence on projection larger than 1 and were thus the most important genes for the explanation of the different mucosal antibacterial response profiles between the 2 patient groups (see Fig. 1 , Supplemental Digital Content 2, http://links.lww.com/IBD/B502). A multivariate factor analysis combining data from fecal microbiota and mucosal antibacterial response (X variables, n ¼ 99) and disease course (Y variable, mild n ¼ 5, moderate/severe n ¼ 8) did not result in an improved discrimination between the groups (R2 ¼ 0.89, Q2 ¼ 0.16, data not shown).
Next, mucosal gene expression of BPI, CXCL2, and CHUK at the time of UC diagnosis was evaluated by RT-PCR in the full patient cohort (n ¼ 44), and it was confirmed that patients with a mild disease course had higher levels of BPI and lower levels of CXCL2 compared with patients with a moderate/severe disease course (Fig. 3A) . In contrast, no differences in gene expression were detected when patients were subgrouped according to high ($9) versus moderate (#8) Mayo score (Fig. 3B ) or according to disease extent at the time of UC diagnosis (Fig. 3C) . BPI expression was also analyzed in noninflamed control patients (n ¼ 7, median age 42 yrs; 4 males/3 females) who showed higher BPI gene expression compared with patients with newly diagnosed UC (n ¼ 44) (median [interquartile range], 0.00024 [0.00020-0.00067] versus 0.00015 [0.00009-0.00021], P ¼ 0.01). Protein expression of BPI was confirmed by immunohistochemistry, where BPI expression was detected in the epithelial cell layer and crypts (Fig. 4) . However, no quantifiable differences in BPI protein expression could be detected by immunohistochemistry between noninflamed controls and UC patients with a mild or a moderate/ severe disease course (data not shown). In patients with newly diagnosed UC, no differences were detected in levels of circulating CXCL2 protein (median [range], 612 pg/mL versus 34 U/mL , P ¼ 0.53) between patients with a mild and a moderate/severe disease course.
BPI Decreases Release of CXCL2 from LPS-stimulated Monocytes
Because higher mucosal expression of BPI and lower mucosal expression of CXCL2 in patients with newly diagnosed UC were associated with the disease course during the 3 years follow-up, the link between BPI and CXCL2 was investigated in a set of in vitro experiments. BPI dose dependently inhibited CXCL2 release from LPS-stimulated monocytes from healthy donors (n ¼ 4, median age 44 yrs; 3 males/1 female) (Fig. 5A,  left) . In addition, the expression of the costimulatory molecule CD80 was decreased with increasing concentrations of BPI (Fig. 5A, right) . No effects of BPI on CXCL2 release could be detected when monocytes were stimulated with peptidoglycan with and without BPI (Fig. 5B) . Taken together, this indicates that high levels of BPI can reduce CXCL2 expression and aid in dampening the immune response to gram-negative bacteria.
Mucosal BPI Expression as a Predictor for the Number of Flares During the 3 Years Follow-up
To determine the relationship between mucosal antibacterial gene expression in patients with newly diagnosed UC and the FIGURE 3. Mucosal expression of BPI, CHUK, and CXCL2 in patients with newly diagnosed UC is associated with disease course. Rectal mucosal biopsies obtained were analyzed for mRNA expression of BPI, CXCL2, and CHUK using RT-PCR. For patients with newly diagnosed UC, gene expression was compared between patients who presented with a mild (blue circles) and a moderate/severe disease course (red circles), respectively (A), between patients with a Mayo score of #8 and $9 (B), and between patients with proctitis, left-sided colitis, or extensive colitis (C) at diagnosis. Gene expression was normalized to the housekeeping genes GAPDH and HPRT. Each symbol represents one individual, and horizontal lines indicate median of the group (n ¼ 44). number of flares during the 3 years follow-up, correlation and linear regression analyses were performed. Mucosal BPI expression at the time of UC diagnosis was negatively correlated to the number of flares (Fig. 6A) , whereas CXCL2 and CHUC did not correlate with the number of flares (r ¼ 0.26, P ¼ 0.087, and r ¼ 20.27, P ¼ 0.082, respectively) during the 3 years follow-up. Furthermore, no correlations were detected between mucosal expression of BPI and Mayo score (Fig. 6B) or fecal calprotectin levels (r ¼ 0.06, P ¼ 0.79) at the time of UC diagnosis. Linear regression analyses identified BPI as a strong predictor, CHUK as a weak predictor, and CXCL2 without predictive ability at the time of UC diagnosis for the number of flares during the 3 years follow-up (Table 3) . Multiple linear regression analyses combining the parameters did not result in a better fit of the model, probably because of collinearity as judged by Eigenvalues of ,0.005 and condition indexes of .25 when combining more than one independent variable. As defined by the highly significant R 2 value (Table 3) , almost 40% of the variance in the number of flares during the 3 years follow-up could be explained by the mucosal BPI expression at diagnosis of disease. Thus, the relation between the predictor (x ¼ BPI) and the outcome (y ¼ number of flares during the 3 years follow-up) can be calculated by the regression equation: 
DISCUSSION
In this study, we have shown that the mucosal antibacterial response profile and the fecal microbiota composition differed between untreated newly diagnosed UC patients with a mild and a moderate/severe disease course. Furthermore, the mucosal antibacterial response profile, but not the fecal bacterial microbiota composition, had high predictive ability when comparing patients with a mild and a moderate/severe disease course. Additionally, the mucosal gene expression of BPI was found to be a good predictor of the disease course; the higher the mucosal expression of BPI at the time of UC diagnosis, the fewer flares during the 3 years follow-up.
The fact that we coexist with our microbiota is well established, and it is also known that numerous diseases, including IBD, are associated with an altered microbiota of the gut. [22] [23] [24] Whether this is the cause or the consequence of the disease and how the microbiota is affected by disease duration and various treatments are currently unknown. To correct for treatment as a confounding factor, we decided to analyze samples from patients with newly diagnosed UC naive to IBD-related medical treatment. Disease duration is more difficult to correct for as patients may have had their symptoms during varying periods of time before seeking health care, but at least all patients had their first flare needing medical care. The fecal microbial composition analysis was limited by the low number of fecal samples obtained, but even though predictability was low, substantial differences between the groups were detected. The microbiota composition has been analyzed previously for treatment-naive UC patients; in the IBSEN II study, untreated UC patients showed only minor fecal microbial differences compared with a noninflamed control group, 25 whereas Shah et al 26 reported that the mucosal microbiome in untreated pediatric patients with UC showed a decrease of Verrucomicrobia at the phylum level and Roseburia at the genus level as compared with non-IBD controls. Concerning microbiota and disease status, a large pediatric cohort of Crohn's disease (the RISK cohort) defined mucosal dysbiotic features correlating with clinical disease severity. 27 In the same cohort, the interaction between the mucosal microbiota and the ileal transcriptome was analyzed resulting in a model where baseline APOA1 expression together with Blautia and Veillonella abundance could predict the 6-month clinical outcome. 28 The microbiota data obtained in the abovementioned studies [25] [26] [27] were all based on 16S rRNA gene sequencing, whereas the analysis used here was based on a defined set of bacterial probes. Although not directly comparable, we can conclude that our data extend beyond previous findings and demonstrate that the altered fecal microbiota profile at diagnosis of disease can also be linked to the clinical outcome in patients with UC.
We were also interested in the link between the microbiota composition and the antimicrobial defense of the host and used an mRNA array to determine the mucosal antibacterial response profile. The global gene expression pattern identified clear differences in the bacterial innate immunity between patients with a mild versus a moderate/severe disease course, especially in BPI, CHUK, and CXCL2 expression. CHUK, also known as inhibitor of nuclear factor kappa-B kinase subunit alpha (IKKa or IKK1), is a protein kinase having an important role in the release of nuclear factor kappa-B to the nucleus. 29 Because CHUK in itself needs to be phosphorylated before exerting its effects 30 and no material for western blot analysis was available, we could not explore this finding further. Regarding CXCL2, we were able to demonstrate that efficient neutralization of LPS via BPI reduced CXCL2 secretion from monocytes. However, as compared with BPI, both CHUK and CXCL2 turned out to be of less importance in relationship to the disease course. We are aware of the fact that gene expression may not always reflect protein expression; therefore, we also analyzed protein expression by immunohistochemistry. BPI protein expression was detected in the epithelial layer and crypts, but the method did not allow for discrimination between noninflamed controls and UC (mild and moderate/severe). For the relationship between BPI and number of flares, the regression analysis showed that mucosal BPI gene expression was a strong predictor for the number of flares during the 3 years follow-up and thus identifies BPI as an important component in gut homeostasis for patients with UC. It is known that BPI is an effector molecule at the mucosal surface with a high affinity (nanomolar) for LPS, acting to neutralize and circumvent cell activation by LPS in polymorphonuclear leukocytes. 31, 32 Higher levels of BPI may therefore help to reduce inflammation and enhance the ability for patients to enter, and maintain, remission.
So far, no clinically validated biomarker predicting disease outcome in patients with newly diagnosed UC has been identified, irrespective of biological source (blood, intestinal biopsy, or stool sample). Here, we found that mucosal gene expression of BPI is closely linked to disease outcome, and as much as 40% of the variance in the number of flares could be explained by mucosal BPI gene expression. Also, via the regression equation, the numbers of flares during the 3 years follow-up can be estimated by the mucosal gene expression level of BPI. In contrast, circulating factors like serum CXCL2 and BPI autoantibodies did not reflect future disease activity. Antineutrophil cytoplasmic antibodies and BPI autoantibodies have been considered possible serological markers for IBD, 33, 34 and we therefore speculated that high levels of BPI autoantibodies could reflect the disease course, but no differences could be detected between the groups. Presumably, it can be difficult to discover a successful circulating biomarker for predicting disease course of patients with IBD because the gut ecology, including the microbiota and the immune defense, is shaped and, to a large extent, maintained locally. There are some limitations of this study, and the low numbers of fecal samples have already been mentioned. In addition, only the microbiota in fecal samples was analyzed, and mucosal microbial composition may yield different results. Furthermore, mucosal samples were only obtained from the inflamed rectum, and it would be of interest to study BPI expression throughout the colon to assess the correlation with disease extent and activity. The most important factor is, however, how a mild versus a moderate/severe disease course was defined. Others have used different strategies to subgroup patients into mild/moderate/severe or mild/relapsing groups based on therapy and incidence of colectomy, 3, 4 relapse rate, need for admission/ surgery and extraintestinal manifestations, 7 or numbers of relapses during the first 3 years. 35 Because it has been shown that a majority of patients with UC experience initial high activity followed by remission or disease with flares of mild severity, 2 we made use of both the number and severity of flares for subgrouping. Patients with few flares (#2) or many flares ($5) were automatically assigned to the groups of mild or moderate/severe disease course, respectively, whereas the severity of the flares was taken into account for patients with 3 to 4 flares. The follow-up concerning health care-seeking patients and medical use showed strong agreement to the group definition. Use of biological therapy was not reported because most of the patients were included before biological therapy was introduced as clinical routine in Sweden. For the regression analysis, the total number of flares during the 3 years follow-up (irrespective of flare severity) was used. Importantly, both the subgrouping of patients according to disease activity together with the number of flares and the number of flares alone highlighted the importance of BPI as a predictive factor, which strengthens the results.
In summary, we have shown that the fecal microbiota composition and the mucosal antibacterial response profile in patients with newly diagnosed UC differ for patients with a mild or a moderate/severe disease course, respectively. Also, the overall mucosal antibacterial response profiles at the time of UC diagnosis showed high predictive ability when comparing patients with a mild and a moderate/severe disease course. Most importantly, mucosal BPI expression is a strong predictor for total number of flares in newly diagnosed patients with UC during the first 3 years of the disease. The predictive value of BPI needs to be validated in larger cohorts of patients and during a longer followup period, before strongly claiming its clinical impact. However, our finding demonstrates an important relationship between a specific molecule of the innate immune system and disease outcome in patients with newly diagnosed UC.
